title,link,date
"Announcement under Regulation 30 (LODR)-Earnings Call Transcript 19h - Cipla Q4 FY25 earnings: 9% revenue growth, new US drug approvals, strong India and Africa growth, positive FDA inspections.",https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=10726a3d-ea15-40af-9631-9f38ebff5582.pdf,"19h - Cipla Q4 FY25 earnings: 9% revenue growth, new US drug approvals, strong India and Africa growth, positive FDA inspections."
Announcement under Regulation 30 (LODR)-Newspaper Publication 2d,https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=36c77a36-3422-489e-ad19-94414c248ffe.pdf,2d
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 13 May - Audio recording of Cipla's Q4 FY25 earnings call available on company website.,https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e5655b9f-ed2a-4c43-b3c5-57364fbba994.pdf,13 May - Audio recording of Cipla's Q4 FY25 earnings call available on company website.
Announcement under Regulation 30 (LODR)-Investor Presentation 13 May - Investor presentation for Q4 and FY 25 financial results,https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2cc43710-cb55-4a7e-8169-057035373bfe.pdf,13 May - Investor presentation for Q4 and FY 25 financial results
"Announcement under Regulation 30 (LODR)-Press Release / Media Release 13 May - Cipla Q4FY25 revenue ₹6,730 Cr (+9%), PAT ₹1,222 Cr (+30%), final dividend ₹13 plus ₹3 special.",https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9b9a765f-32f0-4ec8-a4b2-6d12177e2a49.pdf,"13 May - Cipla Q4FY25 revenue ₹6,730 Cr (+9%), PAT ₹1,222 Cr (+30%), final dividend ₹13 plus ₹3 special."
